SCHEDULE: Citadel Discloses Minimal Stake in Acrivon Therapeutics
Schedule 13G Amendment
Citadel Advisors and related entities report a negligible beneficial ownership of 13 shares in Acrivon Therapeutics.
Summary
- The filing is a Schedule 13G amendment reporting the beneficial ownership of Acrivon Therapeutics, Inc. common stock by Citadel-affiliated entities.
- The reporting persons collectively hold 13 shares of common stock.
- This holding represents 0.0% of the total 38,744,446 shares outstanding as of March 16, 2026.
- The filing confirms that these securities are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing that carries no material information regarding the company's business prospects.
Positives
- The filing provides transparency regarding institutional holdings, ensuring market participants are aware of the minimal position held by these entities.
Negatives
- The holding is statistically insignificant, representing 0.0% of the company's outstanding shares.
Risks
- None identified; the position is de minimis and does not represent a material risk to the issuer or the reporting persons.
Future Outlook
No forward-looking guidance or strategic outlook is provided in this regulatory disclosure.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard regulatory requirements for institutional investors to disclose ownership stakes. A holding of 13 shares is essentially a rounding error and does not indicate any strategic interest or institutional conviction in the issuer.
Comparison to Industry Standards
- This filing is a standard compliance disclosure and does not reflect a competitive or strategic move within the biotechnology sector.
Stakeholder Impact
- No material impact on shareholders, employees, or other stakeholders is expected from this disclosure.
Next Steps
- No future actions or milestones are mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 03/16/2026 | Date used for total shares outstanding calculation. |
| 03/31/2026 | Date of event requiring the filing of this statement. |
| 05/15/2026 | Date of the filing signature. |
Keywords
Acrivon Therapeutics, Citadel, Schedule 13G, Beneficial Ownership, ACRV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.